KRAS and pancreatic adenocarcinoma: Subsequently, we found that the mRNA expression of VPS26A in PAAD samples carrying mutations in KRAS (p-value = 0.0011) or TP53 (p-value = 0.00018), but not the other genes, was significantly higher than that in the corresponding PAAD samples with wild-type KRAS or TP53 (Figure 2F).